凯信远达上涨2.94%，报2.45美元/股，总市值3795.55万美元

Core Insights - CASI Pharmaceuticals (凯信远达) experienced a stock price increase of 2.94%, reaching $2.45 per share, with a total market capitalization of $37.96 million as of August 18 [1] - For the fiscal year ending March 31, 2025, CASI reported total revenue of $6.24 million, reflecting a year-over-year growth of 83.04%, while the net profit attributable to shareholders was a loss of $10.75 million, a decrease of 12.83% compared to the previous year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focusing on advanced treatment solutions for blood cancers in Chinese patients [1] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi in collaboration with local governments [1] - CASI's product and research pipeline addresses multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [1]